Patients on long-term iron replacement with parenteral ferric carboxymaltose (Ferinject) may be at risk of hypophosphataemia, the TGA has advised. There have been 15 reports of hypophosphataemia with ferric carboxymaltose, with severe hypophosphataemia (<0.3mmol/L) in four of six cases where serum phosphate was reported, the regulator says in the latest Medicines Safety Bulletin. The TGA ...
Hypophosphataemia warning for parenteral iron
3 Mar 2020